As liquid biopsy assays gain acceptance for a growing variety of clinical applications, an acute need for highly multiplexed reference materials bearing a broad range of clinically relevant variant types has arisen. But searching for useful remnant patient specimens is prohibitively time-consuming, and single plex cell lines are inefficient and add unnecessary expense.
Seraseq ctDNA v4 reference materials are purpose-built to accelerate the thorough validation and clinical implementation of NGS-based ctDNA assays. Seraseq ctDNA v4 contains an unprecedented 93 variants including SNPs, indels, translocations and CNVs. Seraseq ctDNA v4 is manufactured with a new fragmentation process which results lower background than previous Seraseq ctDNA offerings to support greater confidence at low variant allele frequencies. These orthogonally validated truth-set materials can trim weeks or even months off your assay validation timeline with the most complete coverage of actionable variant types in a single reference sample. With the input of recognized clinical genomics experts, the Seraseq ctDNA v4 Reference Materials focus on clinically relevant variants that provide actionable feedback about patient samples.
FEATURES AND BENEFITS
93 unique multiplexed variants in 71 genes, covering 43 SNVs, 19 deletions, 5 insertions, 4 INDELs, 12 CNVs, and 10 translocations for the broadest coverage of clinically relevant variant types in a single reference material
Four different variant allele frequencies (VAF) – WT (0%), 0.1%, 0.5%, and 5% - challenge your limit-of-detection or match typical AF of solid tumor NGS assays
